Cue Biopharma (CUE) vs GridAI Technologies (GRDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GridAI Technologies (GRDX) has outperformed Cue Biopharma (CUE) over the past year, gaining 20.6% versus a loss of 76.8%. Over five years, CUE leads with a -98.9% price change compared with -100.0% for GRDX. Cue Biopharma is the larger company by market cap ($34.7 million vs $32.4 million), about 1.1 times the size.
Cue Biopharma converts more of its revenue into profit, with a net margin of -96.9% versus -17634.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | GRDX |
|---|---|---|
| Share price | $4.15 | $3.16 |
| Market cap | $34.69M | $32.44M |
| 1-day change | -7.78% | -8.41% |
| YTD return | -54.64% | -32.19% |
| 1-year return | -76.75% | +20.61% |
| 5-year return | -98.92% | -99.99% |
| EPS (TTM) | $-27.80 | $-5.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.47M | $36.25K |
| Revenue growth (YoY) | +195.75% | — |
| Net income (latest FY) | $-26.60M | $-6.39M |
| Gross margin | — | -1813.56% |
| Operating margin | -96.67% | -19539.98% |
| Net margin | -96.85% | -17634.42% |
| 52-week high | $45.50 | $6.93 |
| 52-week low | $2.83 | $1.87 |
| Distance from 52-week high | -90.88% | -54.39% |
| Analyst consensus | none | — |
| Avg. price target upside | +2020.48% | — |
| Average volume | 567.02K | 120.78K |
| Shares outstanding | 8.36M | 10.27M |
| Employees | 29 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRDX has outperformed CUE by 97.4 percentage points over the past year.
- Cue Biopharma is more profitable, keeping -96.9 cents of every revenue dollar as net income versus -17634.4 cents for GridAI Technologies.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About GridAI Technologies
GRDX stock →GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.
Health Care · Biotechnology: Pharmaceutical Preparations
CUE vs GRDX FAQ
Which is bigger, Cue Biopharma or GridAI Technologies?
Cue Biopharma (CUE) is larger, with a market capitalization of $34.69M compared with $32.44M for GridAI Technologies (GRDX).
Which stock has performed better over the past year, CUE or GRDX?
GRDX returned +20.61% over the past 12 months, compared with -76.75% for CUE (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and GridAI Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.